Cellartis AB

Development and commercialisation of more than 30 human embryonic stem cell lines

Cellartis, formerly known as Cell Therapeutics Scandinavia AB, was founded in 2001 by a group of scientists from Gothenburg University and Sahlgrenska University Hospital. The company is organised in the three business areas, which deal with undifferentiated and differentiated human embryonic stem cell lines, drug discovery applications based on human embryonic stem cells, and toxicity testing based on hES cells. Two of the 30 cell lines are listed in the National Institutes of Health (NIH) Human Embryonic Stem Cell Registry. Cellartis is collaborating inter alia with Tanabe Pharmaceuticals (Japan) for Parkinson’s disease, stroke and acute spinal cord injury, and with Amersham Biosciences/GE for cell separation media, and with TATAA Biocenter to develop specific characterisation tools. Healthcare.

Mats Lundwall, CEO
Boo Edgar, Business Development
Johann Hyllner, COO

Anders Vedin, Chairman
Gunnar Fernström
Henrik Wingstrand
Keijo Väkiparta
Annika Espander
Henrik Semb

Biotech Center
413 46 Gothenburg
Sweden
Phone: +46-31-758-09-00
Fax: +46-31-758-09-10

Cellartis provides more than 30 different hES cell lines dedicated for use in all countries permitting hES cell research. The company offers different passages from each cell line including very low passages, subclones of selected hES cell lines and detailed protocols for hES cell handling. Media, tools and feeder cells needed to culture hES cells under optimal culture conditions can also be ordered. Stem cell marker analysis (SSEA-1, -3, -4; TRA-1-60, -1-81 and Oct-4), and genetic characterisation (karyotyping and FISH) are standard procedures enforced to guarantee high quality.

In collaboration with Vitrolife AB, Cellartis has developed VitroHES(TM), a culture medium for undifferentiated hES cells and, VitroPBS (TM), a medium for freezing and thawing of hES cells, both of them serum-free. In collaboration with Swemed Laboratories AB, Cellartis also provides stem cell cutting tools designed for cutting, manipulation, and transfer of hES cell colonies.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.